Cocktail-Solvent Screening to Enhance Solubility, Increase Crystal Yield, and Induce Polymorphs - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Cocktail-Solvent Screening to Enhance Solubility, Increase Crystal Yield, and Induce Polymorphs
The authors propose extending initial solvent screening for a single-solvent system to the cocktail solvent screening of binary and ternary solvent mixtures.


Pharmaceutical Technology
Volume 32, Issue 1

Crystallization from solutions is not only an important step in the fabrication of various functional materials in biological systems, but also a key separation and purification process in the manufacture of many fine chemicals and specialty chemicals, especially pharmaceuticals (1, 2). Pharmaceutical crystallizations are often carried out in batches of organic solvents or mixtures of solvents through temperature cooling (3). Because of the excess properties (i.e., the difference between the real properties and the ideal properties) for a real solution, the solubility of an active pharmaceutical ingredient (API) in a solvent mixture is sometimes higher than its solubility in a single solvent as the activity coefficient decreases (4, 5). The solubility enhancement that the solvent mix offers can bring three main advantages to pharmaceutical batch crystallization:

  • It replaces excellent but environmentally harmful solvents such as tetrahydrofuran (THF), N, N-dimethylformamide (DMF), and N, N-dimethylacetamide (DMA) with greener solvents such as alcohols, acetonitrile, and water
  • It gives a higher crystal yield
  • It increases the degree of supersaturation, thus allowing nucleation to be controlled by the lowest nucleation barrier so that the metastable, instead of the thermodynamically stable crystalline phase, is induced (6–8).

Binary-solvent mixtures result when a second solvent (i.e., an antisolvent or cosolvent) is added to a subsaturated solution until the degree of supersaturation is high enough for crystallization to take place under isothermal conditions. Performing further crystallization in ternary solvent mixtures may be a new method of influencing the nucleation rate, the shape of the product crystals, the size distribution of the entire crystallized mass, aggregate and agglomeration properties, the purity of the crystals, and polymorphism (9–14).

Because solubility, crystal yield, and polymorphism are solvent dependent, solution recrystallization by solvent screening is of fundamental and of foremost importance to many chemical process industries. The process is especially important for manufacturing APIs (15–22). Pharmaceutical companies have a limited amount of time and materials to advance new chemical entities from candidacy to Phase I clinical trials (23).

The aim of this article is to extend initial solvent screening for a single-solvent system to the cocktail solvent screening of binary and ternary solvent mixtures on a small scale through temperature cooling from 60 to 25 C, which is often used in drug development and manufacturing (24).


Figure 1 (IMAGES AND FIGURES ARE COURTESY OF THE AUTHORS)
Sulfathiazole, a valuable antimicrobical sulfa drug used in veterinary medicine (see Figure 1), was chosen for this study mainly because of its commercial value and its five polymorphs, which are well-characterized by Fourier-transform infrared spectroscopy (FTIR), powder X-ray diffraction (PXRD), and differential scanning calorimetry (DSC) (10, 15, 17).

Under the initial solvent-screening strategy of single solvent systems, 24 solvents, mostly useful for scale-up, were selected (25). If all 24 solvents had been taken into account, the possible combinations for binary and ternary solvent mixtures would have been 24! (22!2!) = 276 and 24! (21!3!) = 2024, respectively. However, for the purpose of showing the feasibility of cocktail-solvent screening, the authors limited the screening to three miscible green solvents (acetonitrile, n-propanol, and water) and their combinations. N-propanol and acetonitrile produce Form I and Form IV sulfathiazole crystals, respectively. Water is a common solvent in the manufacture of sulfathiazole (15, 26).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
30%
Breakthrough designations
9%
Protecting the supply chain
39%
Expedited reviews of drug submissions
9%
More stakeholder involvement
13%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here